Is Obesity a Disease? Why It Is Now Treated as a Chronic Condition

• Quotes the exact wording current UK guidance uses, rather than arguing the point in the abstract
• Explains why relapse is described as normal in guidance, not as failure
• Covers the biology, the genetics and the set point model honestly, including what is unproven
• Online consultation with UK registered prescribers, with clinical assessment before any supply

Current UK guidance describes obesity as a chronic, relapsing and progressive condition. That single phrase settles more of this argument than any amount of debate about the word disease.

It matters because it changes what treatment is supposed to look like. A condition that relapses is not managed with a twelve week course and a discharge letter. It is managed as a long-term condition, with ongoing review and support rather than simply a short course of treatment.

This page covers what the guidance says, what the biology is, why weight is genuinely hard to keep off, and how treating obesity as a chronic condition changes in practice.

Key things to know

• Current UK guidance describes obesity as a chronic, relapsing and progressive condition
• Guidance states that relapses are normal, and that support for weight maintenance has to be part of any intervention
• Appetite is regulated by hormones and brain signals rather than decided moment to moment
• Weight loss lowers your calorie requirement and changes appetite signals, which is why maintenance is harder than losing
• Guidance tells clinicians to ask permission before discussing weight and to use non-stigmatising language
• Treatment suitability depends on an individual clinical assessment, and results vary between individuals

Is obesity a disease?

Clinically, obesity is treated as a long-term medical condition in the UK. NICE describes overweight and obesity as chronic, relapsing and progressive conditions associated with an increased risk of illness and premature death. WHO also classifies obesity as a chronic disease.

This complex condition is commonly defined by excess body fat that negatively impacts health outcomes. It is important to recognize obesity as a medical condition influenced by genetic variants and environmental factors, including an obesogenic environment that promotes high calorie food and ultra processed food consumption. Understanding obesity management involves addressing contributing factors such as food intake, lifestyle changes, and physical activity to reduce health risks like heart disease and high cholesterol.

Why the word itself is the contested part

There is no single UK statute that declares obesity a disease. What exists is guidance describing it in the language of chronic disease, and a treatment framework built on that description.

The disagreement that remains is mostly about the word rather than the medicine. Some argue that calling obesity a disease removes personal agency. Others argue that not calling it one leaves people blamed for a condition with substantial biological drivers. Both arguments are about framing, and neither changes what the guidance instructs clinicians to do.

For anyone actually affected, the useful question is not what to call it but what follows from it, which is the rest of this page.

What "chronic, relapsing and progressive" means

Three words, each doing separate work.

Relapsing is the word that changes most

Guidance states that behavioural interventions need to provide support for weight maintenance after the intervention, because overweight and obesity can be a long-term health issue and relapses are normal.

Read that again. Relapses are described as normal in national guidance. If you have lost weight and later regained some of it, that does not automatically mean you have failed. NICE recognises relapse as part of the long-term nature of overweight and obesity.

Is obesity a lifestyle choice or a disease?

The question contains a false alternative. Behaviour and biology are not competing explanations, they are the same system viewed from different distances. Obesity disease is influenced by both lifestyle factors such as diet and physical activity and underlying biological mechanisms including genetics and hormone regulation. The World Health Organization recognises obesity as a complex chronic disease that requires comprehensive management strategies combining healthy diet, increased physical activity, and when appropriate, medical treatments like weight loss surgery or pharmacotherapy. Understanding this interplay helps to diagnose obesity accurately and tailor treatment options effectively in diverse ethnic groups and populations.

What choice explains

What you eat and how much you move determine your energy balance, and energy balance determines your weight. Nobody disputes this, and it is why every treatment in guidance is used alongside diet and activity changes rather than instead of them.

What choice does not explain

Why does appetite differ so much between people eating in the same environment? Why some people regain weight while others do not. Why can weight return even when someone continues many of the behaviours that helped them lose weight.

Those differences are biological, and they are the part willpower framing cannot account for. A useful way to hold both: behaviour is the lever, and biology sets how heavy the lever is for you.

The biology behind it

Obesity disease is influenced by a complex interplay of genetic, hormonal, and environmental factors that affect body composition and how the body stores fat.

Obesity develops through a complex interaction between biological, genetic, behavioural, environmental and social factors. Energy balance is important, but appetite regulation, genetics, sleep, medications, the food environment and other factors can all influence how body weight changes and how difficult it is to maintain weight loss.

Research from the National Heart and Blood Institute highlights that obesity increases inflammation and disrupts hormone signaling, which can lead to metabolic changes and increased risk of other health conditions. Genetic factors contribute substantially to differences in susceptibility to obesity, influencing traits such as appetite regulation, energy expenditure and fat distribution.

The World Obesity Federation promotes awareness of obesity as a disease and supports World Obesity Day to highlight the importance of early intervention and comprehensive treatment strategies. These strategies include lifestyle changes, medical treatments, and in some cases, bariatric surgery to reduce stomach size and support sustainable weight loss.

Understanding that obesity is a chronic disease that results from a combination of factors helps reduce stigma and encourages compassionate care. It also emphasises the need for ongoing management to address the increased risk of complications and to support maintaining a healthy weight over time.

Appetite is regulated, not decided

Hunger and fullness are influenced by hormones and brain signalling as well as by psychological, environmental and behavioural factors. Gut hormones released when you eat, including glucagon-like peptide-1, signal fullness and slow how quickly the stomach empties. Other signals report on longer term energy stores.

Some weight-management medicines act on these appetite and metabolic pathways, helping people feel fuller and/or reducing food intake.

Obesity and genetics

Body weight has a substantial inherited component. Weight and body shape run in families in a way that is not fully explained by shared eating habits, which is why two people in the same household can respond very differently to the same food environment.

What is inherited is not a weight but a tendency: how strong your appetite signals are, how full you feel after a given meal, how much you move without deciding to. Those tendencies then meet an environment, and the outcome is your weight.

Rare single gene causes

A small number of people have obesity caused by a single gene affecting appetite regulation. These conditions are uncommon, usually present in childhood with severe early weight gain, and are identified through specialist assessment rather than routine testing.

They matter here for one reason. Their existence proves that appetite regulation is a biological system that can be altered, which is the principle the common form depends on too.

The environment did change

Population weight rose across decades while human genetics did not. Food became more energy dense, cheaper, more available and more heavily promoted, while daily physical activity fell.

Changes in the environment help explain why population weight increased substantially over time, while genetics alone cannot explain the scale or speed of that change.

Why is obesity hard to reverse?

Because losing weight changes the system in ways that push back. Three mechanisms do most of it.

Your requirement falls as you lose

A smaller body needs fewer calories. The deficit you created at your starting weight therefore narrows every time you lose weight, and at some point reaches zero without you changing anything you eat.

NICE has recommended a dietary deficit of around 600 calories a day as one approach to weight loss, while NHS guidance gives average maintenance figures of around 2,000 calories a day for women and 2,500 for men. These are population averages, not personalised calorie targets. Long term weight management help is largely about noticing that shift and resetting for it.

Appetite signals change after weight loss

Losing fat alters the hormonal signals reporting on energy stores, in the direction of increased appetite. The result is that maintaining a reduced weight often takes more deliberate effort than reaching it, which is the opposite of what people expect.

What set point theory claims

Set point theory proposes that the body defends a particular weight, resisting movement away from it in either direction through appetite and energy expenditure.

It is a model rather than an established fact, and the version in which a fixed weight is permanently defended is not supported. What is well described is that the body resists weight loss actively, through the two mechanisms above. Treat set point as a useful metaphor for that resistance rather than as a mechanism with a number attached.

The evidence that it relapses

Trial data makes the relapsing pattern concrete. In an extension of one trial of a licensed weekly injection, 327 people who came off treatment at week 68 had regained much of the loss by week 120, ending 5.6 per cent below their starting weight against 0.1 per cent for those who had been on placebo.

That is a controlled demonstration of the pattern. Substantial weight was lost, treatment stopped, and most of it returned, in people who had already succeeded once.

The conclusion is not that treatment does not work. The important point is that stopping treatment can be followed by substantial weight regain. This is consistent with obesity behaving as a chronic condition that may require ongoing management.

What treating obesity as a chronic condition changes

Managing obesity as a chronic condition

The practical difference is in what you plan for.

1. Set the plan for years rather than weeks, and choose an approach you could still be doing in twelve months
2. Recalculate your calorie requirement as your weight changes, rather than keeping the original figure
3. Treat maintenance as a separate phase with its own plan, not as the absence of a diet
4. Expect and plan for disrupted periods, since guidance describes relapse as normal
5. Track a trend across four weeks rather than reacting to single readings
6. Keep review points in the diary even when things are going well
7. Address sleep, and any condition affecting mobility or breathing, as part of the plan

Who licensed treatment is for

Eligibility for weight-management medicines depends on the specific medicine, its licensed indication, NICE recommendations and the individual's clinical circumstances. Some medicines are licensed for adults with a BMI of 30 or above, or from 27 where a weight-related condition is present, but NHS eligibility can be narrower. NICE uses lower BMI thresholds when assessing overweight and obesity in people from South Asian, Chinese, other Asian, Middle Eastern, Black African and African-Caribbean backgrounds because cardiometabolic risk can occur at a lower BMI.

The response to treatment is reviewed against medicine-specific criteria. For example, NICE recommends stopping orlistat if at least 5% of initial body weight has not been lost after 12 weeks, while for semaglutide and tirzepatide the relevant review point is six months.

For people who would prefer an oral option, oral weight-management medicines may also be available depending on the medicine, licensing requirements and individual clinical assessment.

The scale of it in the UK

Obesity is common enough that treating it as an individual failing does not survive contact with the figures.

In England, 64.5 per cent of adults aged 18 and over were overweight or obese in 2023 to 2024, and 26.5 per cent were obese, up from 61.2 and 22.6 per cent in 2015 to 2016. Almost one third of adults in England, Scotland and Northern Ireland are living with obesity, and one in four in Wales.

Government estimates put the wider cost to UK society at up to £107 billion a year. Obesity is described in government sources as a risk factor for a range of chronic diseases, including cardiovascular disease, type 2 diabetes, at least 12 kinds of cancer, liver disease and respiratory disease, and is associated with reduced life expectancy.

A condition affecting a substantial proportion of adults across the UK, with well-established health consequences, is a population-health issue as well as an individual clinical issue

Medical Disclaimer

This page is general information, not medical advice, and does not replace assessment by an appropriately qualified healthcare professional. The classifications and guidance described here are intended to help you understand how obesity is approached clinically, and are not a substitute for a personal assessment.

Prescription weight management treatments require a clinical assessment before supply and are appropriate only for some people. Treatment suitability depends on an individual clinical assessment, results vary between individuals, and any medicine should only be used under the supervision of an appropriately qualified prescriber. Speak to a healthcare professional about your own circumstances, particularly if you have other health conditions, take medicines that may affect weight, or are considering prescription weight-management treatment.